Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents

Bibliography

• Abdul-Ghani MA, DeFronzo RA. Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus. Endocr Pract 2008;14:782-90
   PubMedGoogle Scholar
• Kanai Y, Lee WS, You G, The human kidney low affinity Na+/glucose cotransporter SGLT2. J Clin Invest 1994;93:397-404
   PubMed Web of Science ®Google Scholar
• Valtin H. Renal function. Boston: Little, Brown and Company; 1983 . p. 65-8
   Google Scholar
• Ganong WF. Formation and excretion of urine. 22 edition. New York: Lange Medical Publishing; Rev Med Phys 2005:799-834
   Google Scholar
• Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med 2007;261:32-43
   PubMed Web of Science ®Google Scholar
• Nishimura M, Naito S. Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies. Drug Metab Pharmacokinet 2005;20:452-77
   PubMedGoogle Scholar
• Tazawa S, Yamato T, Fujikura H, SLC5A9/SGLT4, a new Na+-dependent glucose transporter, is an essential transporter for mannose, 1,5-anhydro-D-glucitol and fructose. Life Sci 2005;76:1039-50
   PubMed Web of Science ®Google Scholar
• Chen J, Feder J, Neuhaus I, Whaley JM. Tissue expressions profiling of the sodium-glucose co-transporter(SGLT) family: implication for targeting SGLT2 in type 2 diabetes patients. Diabetes 2008;57(Suppl 1):A682
   Google Scholar
• van de Heuvel LP, Assink K, Willemsen M, Monnens L. Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose co-transporter (SGLT2). Hum Genet 2002;11:544-47
   Google Scholar
• Stratton I M, Adler AI, Neil HAW, Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 2000;321:405-12
   PubMedGoogle Scholar
• Poitout V, Robertson RP. Secondary b-cell failure in type 2 diabetes. Endocrinology 2002;43:339-42
   Google Scholar
• He Z, King GI. Microvascular complications of diabetes. Endocrinol Metab Clin North Am 2004;33:215-38
   PubMed Web of Science ®Google Scholar
• Schalkwijk CG, Stehouwer CD. Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin Sci 2005;21:143-59
   Google Scholar
• Handlon AL. Sodium glucose co-transporter 2 (SGLT2) inhibitors as potential antidiabetic agents. Expert Opin Ther Pat 2005;15:1532-40
   Google Scholar
• Isaji M. Sodium-glucose cotransporter inhibitors for diabetes. Curr Opin Investig Drugs 2007;8:285-92
   PubMed Web of Science ®Google Scholar
• Ehrenkranz JRL, Lewis NG, Kahn CR, Roth J. Phlorizin: a review. Diabetes Metab Res Rev 2005;21:31-8
   PubMed Web of Science ®Google Scholar
• Oku A, Ueta K, Arakawa K, T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes 1999;48:1794-800
   PubMed Web of Science ®Google Scholar
• Asano T, Anai M, Sakoda H, SGLT as a therapeutic target. Drugs Future 2004;29:461-66
   Web of Science ®Google Scholar
• Ueta K, Ishihara T, Matsumoto M, Log-term treatment wth the Na+-glucose cotransporter inhibitor T-1095 causes sustained improvement in hyperglycemia and prevents diabetic neuropathy in goto-Kalizaki rats. Life Sci 2005;76:2655-68
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb. WO0174834; 2001
   Google Scholar
• Kissei. WO0228872; 2002
   Google Scholar
• Kissei. WO0116147; 2001
   Google Scholar
• Kotobuchi. C-Gycosides and preparation thereof as antidiabetic agents. US6627611; 2003; GB2359554; 2001
   Google Scholar
• Bristol-Myers Squibb. C-Aryl glucoside SGLT2 inhibitors and method. US6414126; 2002; WO2001027128
   Google Scholar
• Bristol-Myers Squibb. WO2002083066; WO2008002824
   Google Scholar
• Bristol-Myers Squibb. WO2008002824
   Google Scholar
• Bristol-Myers Squibb. WO2003099836
   Google Scholar
• Bristol-Myers Squibb. WO2004063209
   Google Scholar
• Bristol-Myers Squibb. WO2006034489
   Google Scholar
• Meng W, Ellsworth BA, Nirschl AA, Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 2008;51:1145-49
   PubMed Web of Science ®Google Scholar
• Han SP, Hagan D, Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 2008;57:1723-29
   PubMed Web of Science ®Google Scholar
• Kipnes M. Dapagliflozin: an emerging treatment option in type 2 diabetes. Expert Opin Investig Drugs 2009;18:327-34
   PubMedGoogle Scholar
• Washburn WN. Development of renal glucose reabsorption inhibitors. J Med Chem 2009;52:1785-94
   PubMed Web of Science ®Google Scholar
• Jabbour SA, Goldstein BJ. Sodium glucose co-transporter 2 inhibitors. Int J Clin Pract 2008;62:1279-84
   PubMed Web of Science ®Google Scholar
• List JF, Woo V, Morales E, Sodium-glucose co-transporter inhibition with dapagliflozin in type 2 diabetics. Diabetes Care 2009;32:650-7
   PubMed Web of Science ®Google Scholar
• Kotobuki/Astellas. C-Glycosides and salts thereof. US7202350; 2007; WO2004080990
   Google Scholar
• Kotobuki/Astellas. Cocrystal of C-glycoside derivative and L-proline. EP2009010; WO2007114475
   Google Scholar
• Kotobuki/Astellas. Azulene derivatives and salts thereof. US7169761; 2007; WO2004013118
   Google Scholar
• Kotobuki/Astellas. Process for production of azulene derivatives and intermediates for the synthesis of the same. US20070293690; WO2006006496
   Google Scholar
• Kotobuki/Astellas. Choline salt crystals of azulene compound. EP1908757; WO2007007628
   Google Scholar
• Kissei. Fused heterocycle derivative medicinal composition containing the same, and medicinal use thereof. US20070197449; WO2005085265
   Google Scholar
• Kissei. Fused heterocycle derivative medicinal composition containing the same, and medicinal use thereof. US20070197450; WO2005085237
   Google Scholar
• Kissei. 1-substituted-3-beta- D-glucopyranosylated nitrogenous hetero-cycle compounds and medicines containing the same. WO2006054629
   Google Scholar
• Tanabe Seiyaku. Novel SGLT inhibitors. US20080027014; WO2008013321
   Google Scholar
• Mitsubishi Tanabe. Crystalline form of 1-(beta-D-glucopyranosyl)-4-methyl- 3-[-5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate. US20080146515; WO2008069327
   Google Scholar
• Tanabe/Mitsubishi. Novel SGLT inhibitors. US20080027014; WO2008013321
   Google Scholar
• Boehringer Ingelheim. Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture. US20050209166; WO2005092877
   Google Scholar
• Boehringer Ingelheim. Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture. WO2006064033; US20060189548
   Google Scholar
• Boehringer Ingelheim. D-Pyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture. US20060074031; WO2006037537
   Google Scholar
• Boehringer Ingelheim. Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture. WO2007000445
   Google Scholar
• Boehringer Ingelheim. Glucopyranosyl-substituted benzyl-benzonitrile derivatives are sodium-dependent glucose cotransporter inhibitors – useful for the treatment of metabolic disorders. WO2007128749
   Google Scholar
• Boehringer Ingelheim. New glucopyranosyl-substituted benzonitrile derivatives WO2008055870
   Google Scholar
• Boehringer Ingelheim. New glucopyranosylated benzyl-benzene derivatives are SGLT2 inhibitors – useful for the treatment of eg diabetes mellitus. WO2008101939
   Google Scholar
• Boehringer Ingelheim. New glucopyranosylated cyclopropyl-benzene derivatives are SGLT-2 inhibitors – useful for the treatment of metabolic disorders.WO2008020011
   Google Scholar
• Boehringer Ingelheim. New glucopyranosyl-substituted difluorobenzyl benzene derivatives are SGLT2 inhibitors – useful for the treatment of eg type I and II diabetes, insulin resistance, metabolic syndrome, atherosclerosis and obesity. WO2008034859
   Google Scholar
• Boehringer Ingelheim. New crystalline form I of 4-(beta-D-glucopyranos-1-yl)- 1-methyl-2-[4-((S)-tetrahydrofuran- 3-yloxy)-benzyl-benzene – useful as an SGLT2 inhibitor for the treatment of metabolic disorders eg. diabetes. WO2007028814
   Google Scholar
• Boehringer Ingelheim. Crystalline forms of 1-chloro-4-(beta-D- glucopyranos-1-yl)- 2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and its use thereof for preparing medicaments. WO2006117360
   Google Scholar
• Boehringer Ingelheim. New crystalline hydrate and amino acid complex forms of crystalline forms of 1-chloro-4-(beta- D- glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene – useful as an SGLT2 inhibitor in the treatment of type 2 diabetes. WO 2008049923
   Google Scholar
• Taisho. 1-Thio-D-glucitol derivatives. US20080132563; WO2006073197
   Google Scholar
• Taisho. 1-Phenyl 1-thio-D-glucitol derivative. WO2008072726
   Google Scholar
• Taisho. C-Phenyl 1-thioglucitol compound. EP2036901; 2009; WO2008001864
   Google Scholar
• Taisho. C-Phenyl glycitol compound. WO2007136116
   Google Scholar
• Chugai. Novel glucitol derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes. US20080319047; WO2006011502
   Google Scholar
• Chugai. Novel cyclohexane derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes. US20080318874; WO2006011469
   Google Scholar
• Chugai. Spiroketal derivative and use thereof as diabetic medicine. US20090030006; WO2006080421
   Google Scholar
• Chugai. Substituted spiroketal derivative and use thereof as drug for treating diabetes. EP2048153; 2009; WO2008013280
   Google Scholar
• Chugai. Fused ring spiroketal derivative and use thereof as drug for treating diabetes. EP2048152; 2009; WO2008013277
   Google Scholar
• Chugai. Thioglucose spiroketal derivative and use thereof as therapeutic agent for treating diabetes. EP2072522; 2009; WO2008044762
   Google Scholar
• Theracos. Glucose transport inhibitors and methods of use. WO2007140191
   Google Scholar
• Theracos. Benzylic glycoside derivatives and methods of use. US20080242596; WO2008122014
   Google Scholar
• Theracos. Spiroheterocyclic glycosides and methods of use. WO2008083200
   Google Scholar
• Theracos. Benzylbenzene derivatives and methods of use. WO2009026537
   Google Scholar
• Lexicon. Inhibitors of sodium glucose co-transporter 2 and methods of use. US20080221164
   Google Scholar
• Lexicon. Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors. US20090030198; WO2009014970
   Google Scholar
• Jansen and Mitsubishi Tanabe. Thienyl-containing glycopyranosyl derivatives as antidiabetics. WO2008070609
   Google Scholar
• Tanabe Seiyaku. N-Glucoside compounds having an inhibitory activity against sodium-dependent glucose transporter inhibitor. US7521430; 2009
   Google Scholar
• Tanabe Seiyaku. Pharmaceutical compositions containing N-glucoside compounds. JP2006232825
   Google Scholar
• Tanabe Seiyaku. Novel compounds. US200502333988; JP200850353
   Google Scholar
• Tanabe Seiyaku. Indole derivatives. US20080119422; WO2006080577
   Google Scholar
• Tanabe Seiyaku. Indole derivatives. US20080027122; WO2008013322
   Google Scholar
• Kissei. 1(Beta-D-glycopyranosyl)- 3-substituted nitrogenous heterocyclic compounds, medicinal composition containing the same, and medicinal use thereof. US20080139484; WO2006035796
   Google Scholar
• Kissei. Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs. US7375113; 2008; WO2005085267
   Google Scholar
• Kissei. Phenol derivative, medicinal composition containing the same, and medicinal use thereof. WO2005095429
   Google Scholar
• Kissei. 1-Substituted-7-(beta- D-glycopyranosyloxy)indole compound and pharmaceutical containing the same. WO2006087997
   Google Scholar
• Daiichi Sankyo. Benzyl phenyl glucopyranoside derivative. EP2048150; 2009; WO2008016132
   Google Scholar
• Boehringer Ingelheim. Crystalline form of 1′-(1-methylethyl)-4′-[(2-fluoro- 4-methoxyphenyl)methyl]-5′-methyl- 1H-pyrazol-3′-O-beta-D-glucopyranoside, a method for its preparation and the use thereof for preparing medicaments. US20070244176; WO2007080170
   Google Scholar
• Boehringer Ingelheim. Methods for preventing and treating metabolic disorders and new pyrazole-O-glycoside derivatives. US20070072813; WO2007014895
   Google Scholar
• Taisho. Aryl 5-thio-beta-D-glucopyranoside derivatives and therapeutic agents for diabetes containing the same. US7414072; 2008; WO2004014930; WO2004014931
   Google Scholar
• Taisho. Heteroaryl 5-thio-beta- D-glucopyranoside derivatives and therapeutic agents for diabetes containing the same. US7439232
   Google Scholar
• Taisho. The diabetes mellitus treating agent which comprises phenyl 5-thioglucoside compound [machine translation]. JP2009107948
   Google Scholar
• Taisho. The diabetes mellitus treating agent which comprises pyrazolyl 5-thio-glucoside compound [machine translation]. JP2009107947
   Google Scholar
• Merck GMBH. New 2-phenyl- 3-phenylamino-indolizine derivatives, are sodium-dependent glucose cotransporter inhibitors useful for treating type 1 and type 2 diabetes. WO2008071288
   Google Scholar
• Merck GMBH. Preparation of benzimidazoles as antidiabetic agents. WO2008101586
   Google Scholar
• Merck GMBH. New 3-amino-imidazo(1,2-a)pyridine compounds are sodium dependent glucose cotransporter inhibitors useful to treat e.g. type 1 and type 2 diabetes, nephropathy, retinopathy, neuropathy, syndrome X and obesity, and to reduce blood sugar. WO2008046497
   Google Scholar
• Merck GMBH. New imidazo(1,2-a)pyrimidine compounds are sodium dependent glucose cotransporter 1 inhibitors useful to treat and prevent e.g. type 1 and type 2 diabetes, obesity, myocardial infarction, thrombosis, atherosclerosis, cancer and psoriasis. WO2009049731
   Google Scholar
• Grempler R, Thomas L, Eckhardt M, In vitro properties and in vivo effect on urinary glucose excretion of BI 10773, a novel selective SGLT2 inhibitor. American Diabetes Association Meeting 2009; Abst P-521
   Google Scholar
• Liang Y, Arakawa K, Martin T, JNJ-28431754/TA-7284, an SGLT inhibitor, lowers blood glucose and reduces body weight in obese and type 2 diabetic animal models. American Diabetes Association Meeting 2009; Abst P-534
   Google Scholar
• Adapted from Silverman M, Turner RJ. Handbook of Physiology. Oxford: Oxford University Press; 1992 . p. 2017-38
   Google Scholar